Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Biomarkers for inhibitors with anti-angiogenic activity

A biomarker and angiogenesis technology, applied in biomaterial analysis, drug combination, antineoplastic drugs, etc., can solve problems such as no benefit, restricted tumor growth, and reduced vascular system

Active Publication Date: 2011-11-30
MERCK PATENT GMBH
View PDF12 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Decreased vasculature and restricted tumor growth in early-stage tumors with anti-VEGF therapy, such as an anti-VEGF antibody (bevacizumab)
However, continued antiangiogenic therapy with bevacizumab in metastatic tumors produced no benefit in a retrospective analysis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biomarkers for inhibitors with anti-angiogenic activity
  • Biomarkers for inhibitors with anti-angiogenic activity
  • Biomarkers for inhibitors with anti-angiogenic activity

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0143] The term "angiogenesis-associated disease" promotes a large number of diseases or disorders that result directly from deregulated angiogenesis or are biased in the indirect effects of deregulated angiogenesis. These numerous diseases include oncological disorders, cardiovascular diseases, inflammation, autoimmune diseases, degenerative disorders, eye disorders. Dysregulated angiogenesis can be induced by a variety of pathological stimuli.

[0144] The term "anti-angiogenic effect" means blocking or at least inhibiting angiogenesis. In the context of the present invention, anti-angiogenic drugs or substances are preferably used to combat angiogenesis-associated diseases by limiting the pathological formation of new blood vessels (angiogenesis), and the disease symptoms mediated by angiogenesis are due to the administration of anti-angiogenic relieved by drugs.

[0145] The term "biomarker" refers to a substance used as an indicator of a biological state. It is a chara...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a method for assessing the effect of integrin inhibitors and small molecule ATP site directed multi kinase inhibitors on angiogenesis by the use of certain identified biomarkers. This method is notably beneficial for the determination of the efficacy of integrin inhibitors and small molecule ATP site directed multi-kinase inhibitors mainly used for the treatment of angiogenesis associated diseases such as cancer. Especially, the invention relates to biomarkers linked to angiogenesis that are preferably accessible in body fluids and therefore allow analysis of target modulation in a non-invasive way. The use of said biomarkers for the screening of compounds with integrin-inhibitory activity is also disclosed.

Description

technical field [0001] The present invention relates to methods for assessing the effects of integrin inhibitors and small molecule ATP site-directed multikinase inhibitors on angiogenesis by using certain identified biomarkers. This method is particularly useful for determining the efficacy of integrin inhibitors and small molecule ATP site-directed multikinase inhibitors that are primarily used in the treatment of angiogenesis-related diseases such as cancer. In particular, the present invention relates to biomarkers associated with angiogenesis, which are preferably accessible in body fluids and thus allow analysis of target regulation in a non-invasive manner. Also disclosed is the use of the biomarker for screening compounds having integrin inhibitory activity. Background technique [0002] Angiogenesis is broadly applicable to the formation of new blood vessels from pre-existing vasculature. Proliferation of endothelial cells undergoing DNA synthesis is a common hall...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/574
CPCG01N2800/52G01N2500/10G01N33/57484A61P35/00G01N33/57488
Inventor J·拜伦斯
Owner MERCK PATENT GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com